Efficacy and safety of regorafenib or TAS-102 in patients with metastatic colorectal cancer refractory to standard therapies

Anticancer Research

Volumn 36, Issue 8, 2016, Pages 4299-4306

  Sueda, Toshinori ^a   Sakai, Daisuke ^b   Kudo, Toshihiro ^b   Sugiura, Takashi ^c   Takahashi, Hidekazu ^a   Haraguchi, Naotsugu ^a   Nishimura, Junichi ^a   Hata, Taishi ^a   Hayashi, Taro ^d   Mizushima, Tsunekazu ^a   Doki, Yuichiro ^a   Mori, Masaki ^a   Satoh, Taroh ^b  

^a Department of Gastroenterological Surgery ^*  (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c Departments of Medical Oncology   (Japan)

^d Saito Yukoukai Hospital   (Japan)

Author keywords

Metastatic colorectal cancer; Regorafenib; TAS 102

Indexed keywords

CREATININE; REGORAFENIB; TIPIRACIL PLUS TRIFLURIDINE; CARBANILAMIDE DERIVATIVE; DRUG COMBINATION; PYRIDINE DERIVATIVE; TRIFLURIDINE; URACIL;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DESQUAMATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERAMMONEMIA; HYPERBILIRUBINEMIA; HYPERTENSION; LIVER TOXICITY; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; ORAL MUCOSITIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; SIDE EFFECT; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOICE DISORDER; VOMITING; ADVERSE DRUG REACTION; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; DRUG COMBINATION; METASTASIS; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PHENYLUREA COMPOUNDS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TRIFLURIDINE; URACIL;

EID: 84991745859     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global Cancer Statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
2. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S and Cervantes A: ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23: 2479-516, 2012.
3. Miyamoto Y, Watanabe M, Sakamoto Y, Shigaki H, Murata A, Sugihara H, Etoh K, Ishimoto T, Iwatsuki M, Baba Y, Iwagami S, Yoshida N and Baba H: Evaluation of the necessity of primary tumor resection for synchronous metastatic colorectal cancer. Surg Today 44: 2287-2292, 2014.
4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): colon cancer. Version 2. 2016. http://www. nccn. org/professionals/ physician-gls/ pdf/colon. pdf. Accessed 26 Jan 2016. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): rectal cancer. Version 2. 2016. http://www. nccn. org/professionals/physician- gls/ pdf/rectal. pdf. Accessed 26 Jan 2016.
5. Saeki H, Emi Y, Kumashiro R, Otsu H, Kawano H, Ando K, Ida S, Kimura Y, Tokunaga E, Oki E, Morita M, Shimokawa M and Maehara Y: Impact of second-line and later cetuximabcontaining therapy and KRAS genotypes in patients with metastatic colorectal cancer: a multicenter study in Japan. Surg Today 44: 1457-1464, 2014.
6. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH and Zopf D: Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129: 245-255, 2011.
7. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; CORRECT Study Group: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo controlled, phase 3 trial. Lancet 381: 303-312, 2013.
8. Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J, Kim TW; CONCUR Investigators: Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 16: 619-629, 2015.
9. Fujiwara Y and Heidelberger C: Fluorinated pyrimidines. XXXVII. The incorporation of 5-trifluoromethyl-2-deoxyuridine into the deoxyribonucleic acid vaccinia virus. Mol Pharmacol 6: 281-291, 1970.
10. Emura T, Suzuki N, Yamaguchi M, Ohshimo H and Fukushima M: A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol 25: 571-578, 2004.
11. Suzuki N, Nakagawa F, Nukatsuka M and Fukushima M: Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks. Exp Ther Med 2: 393-397, 2011.
12. Fukushima M, Suzuki N, Emura T, Yano S, Kazuno H, Tada Y, Yamada Y and Asao T: Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides. Biochem Pharmacol 59: 1227-1236, 2000.
13. Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Sugimoto N, Tsuji Y, Moriwaki T, Esaki T, Hamada C, Tanase T and Ohtsu A: TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13: 993-1001, 2012.
14. Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group: Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372: 1909-1919, 2015.
15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1). Eur J Cancer 45: 228-247, 2009.
16. US Department of Health and Human Services: Common Terminology Criteria for Adverse Events (CTCAE). Version 4. 0. Washington, DC: US Department of Health and Human Services, 2010.
17. Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Büchert M, Christensen O, Jeffers M, Heinig R, Boix O and Mross K: Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer 106: 1722-1727, 2012.
18. Yoshino T, Komatsu Y, Yamada Y, Yamazaki K, Tsuji A, Ura T, Grothey A, Van Cutsem E, Wagner A, Cihon F, Hamada Y and Ohtsu A: Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. Invest New Drugs 33: 740-750, 2015.
19. Salvatore L, Rossini D, Moretto R, Cremolini C, Schirripa M, Antoniotti C, Marmorino F, Loupakis F, Falcone A and Masi G: TAS-102 for the treatment of metastatic colorectal cancer. Expert Rev Anticancer Ther 15: 1283-1292, 2015.
20. Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A and Van Cutsem E: Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 16: 937-948, 2015.
21. Komatsu Y, Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Baba H, Tsuji A, Yamaguchi K, Muro K and Ohtsu A: The Value of Thymidine Kinase 1 (TK1) and Thymidine Phosphorylase (TP) Expression as Predictive Factors With the Treatment Efficacy of TAS-102, a Novel Antitumor Agent, in Patients (pts) With Metastatic Colorectal Cancer (mCRC). Eur J Cancer 47(Suppl 1): S-421, 2011.
22. Marks EI, Tan C, Zhang J, Zhou L, Yang Z, Scicchitano A and El-Deiry WS: Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FUcontaining combination therapies and regorafenib monotherapy. Cancer Biol Ther 16:1710-1719, 2015.
23. Napolitano S, Martini G, Rinaldi B, Martinelli E, Donniacuo M, Berrino L, Vitagliano D, Morgillo F, Barra G, De Palma R, Merolla F, Ciardiello F and Troiani T: Primary and acquired resistance of colorectal cancer to anti-EGFR monoclonal antibody can be overcome by combined treatment of regorafenib with cetuximab. Clin Cancer Res 21: 2975-2983, 2015.
24. Lu CY, Yeh YS, Huang CW, Ma CJ, Yu FJ and Wang JY: FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping. Onco Targets Ther 7: 2143-2146, 2014.
25. Emura T, Murakami Y, Nakagawa F, Fukushima M and Kitazato K: A novel antimetabolite, TAS-102 retains its effect on FUrelated resistant cancer cells. Int J Mol Med 13: 545-549, 2004.
26. Doi T, Yoshino T, Fuse N, Boku N, Yamazaki K, Koizumi W, Shimada K, Takinishi Y and Ohtsu A: Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. Invest New Drugs 33: 1068-1077, 2015.